Emiko Koumura

Pharmacokinetics of a Single Dose of Azilsartan in Pediatric Patients: A Phase 3, Open-Label, Multicenter Study

H. Okamoto, K. Enya, B. Saji, 2018, Advances in Therapy.

Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.

J. DeJongh, M. Danhof, K. Kaku, 2015, Diabetes technology & therapeutics.

Evaluation of the Long-term Durability and Glycemic Control of FPG and HbA1c for Pioglitazone in Japanese Patients with Type 2 Diabetes

J. DeJongh, M. Danhof, K. Enya, 2015 .

Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment

Y. Shimasaki, M. Itou, K. Shimizu, 2018, Clinical Drug Investigation.

Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis.

K. Tohyama, Shuntarou Tsuchiya, K. Enya, 2018, Biochemical and biophysical research communications.

Pharmacokinetics, safety, and tolerability of sodium phenylacetate and sodium benzoate in healthy Japanese volunteers: A phase I, single-center, open-label study.

K. Shimizu, Kimitoshi Nakamura, Emiko Koumura, 2022, Drug metabolism and pharmacokinetics.

Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism

H. Ueno, K. Takeuchi, Lihong Shi, 2016, PloS one.